More evidence for implant-based breast reconstruction
Menée auprès d'une cohorte de 2 108 patientes ayant subi entre 2014 et 2016 une mastectomie pour traiter ou prévenir un cancer du sein (âge : 16 ans ou plus), cette étude évalue, du point de vue de la survenue de complications nécessitant de nouvelles interventions (retrait de l'implant ou de l'expanseur, traitement d'infections, réhospitalisation, ...), la sécurité à court terme d'une mastectomie suivie immédiatement d'une reconstruction mammaire par implant et utilisation ou non d'un treillis biologique ou synthétique de renfort
The scarcity of randomised controlled trials is a key issue in surgical research. The dearth of trials results from several methodological challenges, and because of surgeons' reluctance to be involved in study design.1
Nonetheless, experimental research is crucial to the generation of high-quality data to assess the effects of new procedures or devices before introducing them into standard practice. This insufficiency of high-level evidence becomes a paradox when dealing with implant-based breast reconstruction. Despite this technique being the most common surgical procedure for breast reconstruction worldwide, the number of patients involved in randomised trials is very low.
The Lancet Oncology , commentaire en libre accès, 2018